Guard Therapeutics International AB

Guard Therapeutics is a Swedish clinical-stage biotech focused on kidney diseases. Its lead candidate RMC-035, based on the alpha-1-microglobulin (A1M) protein, is in Phase 2b (POINTER study) for kidney protection in open-heart surgery and has received FDA Fast Track Designation. It also develops GTX peptides for chronic kidney disease. Listed on Nasdaq First North.